CTOR
Citius Oncology, Inc.
Drug Manufacturers - Specialty & Generic · Healthcare · United States
0.55
close · 2026-10-30
value
10
cheaper than peers10
quality
18
stronger fundamentals18
ranked against
Drug Manufacturers - Specialty & Generic
value
quality
41 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 1.45× | 81 |
| cash flow yield, 3 years ago | 0.0% | 60 |
| cash flow yield, 2 years ago | 0.0% | 40 |
| earnings yield, 3 years ago | -13.8% | 26 |
| earnings yield, 2 years ago | -32.2% | 21 |
| cash flow yield, latest year | -19.2% | 11 |
| cash flow yield, 1 year ago | -8.3% | 11 |
| price to sales | 10.44× | 9 |
| earnings yield, latest year | -61.4% | 6 |
| earnings yield, 1 year ago | -56.0% | 6 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 10.8% | 90 |
| return on equity | -119.9% | 7 |
| operating margin | -1716.2% | 4 |
3 of 4 measures available
Facts
| market cap | $59M |
| free cash flow | -$23.6M |
| employees | none reported |
| first trade | 2022-12-08 |
| next earnings | not reported |
| fundamentals updated | 2026-08-17 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.34 | -0.31 | -0.18 | -0.08 |
| free cash flow | -$11.2M | -$4.9M | $0 | $0 |
| net income | -$24.8M | -$21.1M | -$12.7M | -$5.4M |
| revenue | $0 | $0 | $0 | $0 |